ELVN NASDAQ
Boulder, CO 80301
US
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Hohl Benjamin | S-Sale | 324 | $49.97 | 2026-07-17 |
| Hohl Benjamin | S-Sale | 369 | $51.48 | 2026-07-17 |
| Hohl Benjamin | S-Sale | 2,564 | $52.32 | 2026-07-17 |
| Hohl Benjamin | S-Sale | 2,638 | $53.38 | 2026-07-17 |
| Hohl Benjamin | S-Sale | 123 | $53.87 | 2026-07-17 |